<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04880070</url>
  </required_header>
  <id_info>
    <org_study_id>SW-MCPM-2021</org_study_id>
    <nct_id>NCT04880070</nct_id>
  </id_info>
  <brief_title>Post-Market Clinical Follow Up Study to Collect Additional Data and Imaging</brief_title>
  <official_title>Post Market Clinical Follow Up Study to Collect Additional Data and Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, multi-center clinical study to collect additional data and&#xD;
      imaging for the ViaSure device.The intended use of the ViaSure device used in this study is&#xD;
      to assess the usability and tissue response to shock wave treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 50 subjects will be enrolled at 2 study centers. Subjects will attend a&#xD;
      screening/pretreatment visit which may be performed on the same day as the treatment visit.&#xD;
      Subjects may receive up to 5 treatments with the study device. Follow up visits may occur 30&#xD;
      and 90 days post last treatment visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Discomfort</measure>
    <time_frame>From start of treatment 1 to end of treatment 5 (with each treatment being 3-14 days apart)</time_frame>
    <description>The average treatment discomfort of all of the subjects' treatments. Subjects will be asked to report the general level of treatment discomfort on a scale of 0 (none) to 10 (maximum intolerable pain) using the universal pain assessment tool.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Connective Tissue Defect</condition>
  <arm_group>
    <arm_group_label>Shockwave Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Shockwave device will be used on multiple areas of the body for the purpose of treating connective tissue.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Shockwave Treatment</intervention_name>
    <description>Self-controlled, single-arm group using the Shockwave device.</description>
    <arm_group_label>Shockwave Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy male or female 18 - 65 years of age.&#xD;
&#xD;
          -  Willing to undergo treatments with the SoftWave device.&#xD;
&#xD;
          -  Understands and accepts obligation not to receive any other procedures on the&#xD;
             treatment area through the length of the study.&#xD;
&#xD;
          -  Understands and accepts the obligation and is logistically able to be present for all&#xD;
             visits.&#xD;
&#xD;
          -  Is willing to comply with all requirements of the study and sign the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is pregnant or of childbearing potential and not using medically effective birth&#xD;
             control, or has been pregnant in the last 3 months, currently breast feeding or&#xD;
             planning a pregnancy during the study.&#xD;
&#xD;
          -  The subject has a pacemaker or implantable defibrillator.&#xD;
&#xD;
          -  The subject has a severe coagulation disorder.&#xD;
&#xD;
          -  The subject has open epiphyseal plates.&#xD;
&#xD;
          -  The subject has recently had a steroid injection.&#xD;
&#xD;
          -  The subject is currently enrolled in an investigational drug or device trial, or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             in the area to be treated 6 months to entering this study.&#xD;
&#xD;
          -  The subject has any condition or is in a situation which, in the Investigator's&#xD;
             opinion, may put the subject at significant risk, may&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Civiok</last_name>
    <role>Study Director</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Trimper</last_name>
    <phone>(978) 256-4200</phone>
    <email>jamie.trimper@cynosure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cynosure, Inc.</name>
      <address>
        <city>Westford</city>
        <state>Massachusetts</state>
        <zip>01886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Doherty</last_name>
    </contact>
    <investigator>
      <last_name>Sean Doherty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2021</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

